Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.44 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CASP6 | P55212 | 2/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5504251 | 0.86 | CASP3 (0.43) | NOTUMHPGDSMN1; SMN2CYP2D6CYP2C9 | |
| SCHEMBL7688831 | 0.86 | SMN1; SMN2 (0.57) | NOTUMHPGDSMN1; SMN2CYP2D6CYP2C9 | |
| SCHEMBL4415354 | 0.86 | SMN1; SMN2 (0.57) | NOTUMHPGDSMN1; SMN2CYP2D6CYP2C9 | |
| SCHEMBL3227444 | 0.85 | NOTUM (0.49) | NOTUMHPGDOPRM1OPRK1OPRL1 | |
| SCHEMBL4656372 | 0.85 | NOTUM (0.49) | NOTUMHPGDSMN1; SMN2OPRM1OPRK1 | |
| SCHEMBL12769714 | 0.84 | DRD1 (0.40) | NOTUMHPGDSMN1; SMN2CYP2D6CYP2C9 | |
| SCHEMBL29896794 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP2D6CYP2C9OPRM1OPRK1 | |
| SCHEMBL5956393 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP2D6CYP2C9OPRM1OPRK1 | |
| SCHEMBL21142478 | 0.82 | NOTUM (0.46) | NOTUMHPGDOPRM1OPRK1OPRL1 | |
| SCHEMBL5506594 | 0.82 | MEN1 (0.51) | HPGDSMN1; SMN2BMPR1BBMPR1AACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| CN-115636778-B | Synthesis method of 3-quaternary carbon substituted indoline-2-ketone compound | 常州大学 | 2024-05-07 | — | — | CN | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | GENENTECH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | GENENTECH, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115636778-A | Synthetic method of 3-quaternary carbon substituted indoline-2-ketone compound | 常州大学 | 2023-01-24 | — | — | CN | disclosed |
| US-11530208-B2 | Imidazo[4,5-C]pyridine derived SSAO inhibitors | PROXIMAGEN, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-11364240-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-7202251-B2 | Bicyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007033175-A1 | INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007003965-A1 | SUBSTITUTED CYCLOHEXYL DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | JOSYULA VARA PRASAD V N | 2006-10-12 | — | — | US | disclosed |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | LUEHR GARY W | 2006-02-09 | — | — | US | disclosed |
| US-5389661-A | Treats hypertension, heart failure, glaucoma and hyperaldosteronism | WARNER-LAMBERT COMPANY (US) | 1995-02-14 | — | — | US | disclosed |
| US-5322950-A | Treating hypertension, hyperaldosteronism, glaucoma, heart failure | WARNER-LAMBERT COMPANY (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0208510-B1 | 1-SUBSTITUTED OXINDOLE-3-CARBOXAMINES AS ANTIINFLAMMATORY AND ANALGESIC AGENTS | PFIZER INC. (US) | 1991-09-11 | — | — | EP | disclosed |
| US-4486442-A | ANTIANAPHYLACTIC | BOEHRINGER MANNHEIM GMBH (DE) | 1984-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364240-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | NOTUM 3861/4885HPGD 653/4885SMN1; SMN2 1871/4885 |
| US-11643421-B2 | Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer | PIK3CA, PIK3CD, PIK3CB | NOTUM 599/4885HPGD 3005/4885SMN1; SMN2 3820/4885 |
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | OXA1L, MRPL21, RPS27L | NOTUM 4215/4885HPGD 3521/4885SMN1; SMN2 3990/4885 |
| US-20230242550-A1 | PROCESS FOR THE PREPARATION OF TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS FOR USING THE SAME FOR THE TREATMENT OF CANCER | PIK3CA, PIK3CD, PIK3CB | NOTUM 599/4885HPGD 3005/4885SMN1; SMN2 3820/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NOTUM 4116/4885HPGD 861/4885SMN1; SMN2 2611/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | NOTUM 1676/4885HPGD 1054/4885SMN1; SMN2 524/4885 |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | NOTUM 3727/4885HPGD 1259/4885SMN1; SMN2 1719/4885 |
| US-11530208-B2 | Imidazo[4,5-C]pyridine derived SSAO inhibitors | PNPO, SQOR, HAO1 | NOTUM 4454/4885HPGD 453/4885SMN1; SMN2 477/4885 |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | OXA1L, OXSR1, OXER1 | NOTUM 4372/4885HPGD 3549/4885SMN1; SMN2 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.